Malignant TumorNCT05616182
Application of LARS Ligament in Bone Prosthesis Replacement
An observational study of Malignant Tumor, run by Henan Cancer Hospital at 1 site in China.
Trial summary
This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Malignant Tumor
- What is being tested?
- LARS ligament and bone prosthesis replacement was performed
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 30 Dec 2024to 28 Feb 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients undergoing LARS ligament and bone prosthesis replacement
Who may be able to join
- Men and women of all ages are welcome.
- Pathologically confirmed in our hospital as a subtype of malignant tumor.
- He received LARS ligament and bone prosthesis replacement at our hospital.
Who cannot join
- Not Applicable.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Zhengzhou, Henan
Tian Zhichao, Dr., +8618737187831, tianzhichhaoyy@163.com
About this study
Official title: A Prospective, Real-world, Single-center, Cohort Study of LARS Ligaments in Bone Tumors
This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.
Read the detailed description
This is a single-center prospective real-world observational study of 100 eligible patients with bone tumors who are scheduled to undergo LARS ligament implantation and/or bone prosthesis replacement in Henan Cancer Hospital in the next 10 years. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.
- Conditions
- Malignant Tumor
- Being tested
- LARS ligament and bone prosthesis replacement was performed
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LARS ligament and bone prosthesis replacement was performedOther
To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
| Study group | Role | What they receive |
|---|---|---|
| LARS ligament and bone prosthesis replacement was performed | To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital. Receives: Other: LARS ligament and bone prosthesis replacement was performed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative complications
Complications of patients undergoing LARS ligament and bone prosthesis replacement.
Measured: From surgery to 24 months after surgery
Limb function
Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.
Measured: Patients were enrolled until 24 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2022
- Study start30 Dec 2024 (estimated)
- Primary completion28 Feb 2032 (estimated)
- Study completion28 Feb 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Henan Cancer Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Wang Jiaqiang, Henan Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05616182
- Sponsor's protocol ID
- ZZUSC-17
- Status last verified
- Aug 2023
- First submitted
- 31 Oct 2022
- Last updated
- 24 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Real-world, Single-center, Cohort Study of LARS Ligaments in Bone Tumors
- ClinicalTrials.gov ID
- NCT05616182
- Acronym / sponsor ID
- ZZUSC-17
- Conditions
- Malignant Tumor
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Henan Cancer HospitalOther government
- Study start
- 30 Dec 2024 (estimated)
- Primary completion
- 28 Feb 2032 (estimated)
- Study completion
- 28 Feb 2032 (estimated)
- First posted
- 15 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, prospective, real-world observational study designed to enroll all patients eligible for enrollment. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.
Detailed description
This is a single-center prospective real-world observational study of 100 eligible patients with bone tumors who are scheduled to undergo LARS ligament implantation and/or bone prosthesis replacement in Henan Cancer Hospital in the next 10 years. Basic data, treatment methods, postoperative complications and limb function were collected. The differences in postoperative complications, postoperative limb function and so on between patients who underwent LARS ligament implantation and bone prosthesis replacement (ligament group) and patients who underwent bone prosthesis replacement (control group) were compared.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| LARS ligament and bone prosthesis replacement was performed | – | Other: LARS ligament and bone prosthesis replacement was performedTo report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients undergoing LARS ligament and bone prosthesis replacement
Key inclusion criteria (3 listed)
- Men and women of all ages are welcome.
- Pathologically confirmed in our hospital as a subtype of malignant tumor.
- He received LARS ligament and bone prosthesis replacement at our hospital.
Key exclusion criteria (1 listed)
- Not Applicable.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LARS ligament and bone prosthesis replacement was performedTo report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital. | Other | LARS ligament and bone prosthesis replacement was performed |
Primary outcome
Postoperative complications
Time frame: From surgery to 24 months after surgery
Complications of patients undergoing LARS ligament and bone prosthesis replacement.
Limb function
Time frame: Patients were enrolled until 24 months after surgery
Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Malignant Tumor
RecruitingPhase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Lymphoma, Non-Hodgkin Lymphoma
RecruitingPhase 1/2
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Brain Tumor, Cancer
Active, not recruiting
A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Active, not recruiting
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
Human Papilloma Virus (HPV) Vaccine
RecruitingObservational study
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Brain Metastases, Bone Metastases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Zhengzhou, China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Tumor, run by Henan Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative complications (time frame: From surgery to 24 months after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2024.